InfraRedX

InfraRedX’s LipiScan™ IVUS Coronary Imaging System was highlighted at the ACC.11 and i2. InfraRedX, Inc., a medical device company that provides intelligent cardiovascular diagnostic imaging technologies, exhibited its LipiScan™ IVUS Coronary Imaging System in several oral and poster presentations during the meeting.

InfraRedX, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraRedX’s LipiScan™ IVUS Coronary Imaging System includes the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to visualize and characterize the intracoronary lipid core plaques (LCP) that complicate stenting and are suspected of causing the majority of heart attacks.

The LipiScan IVUS Coronary Imaging System presented is the world’s first and only intravascular imaging system that combines and co-registers grayscale intravascular ultrasound (IVUS) with the company’s proprietary near infrared spectroscopy lipid core plaque detection technology.

“We are pleased with the level of interest the LipiScan IVUS has received since its launch last year, and we look forward to the numerous presentations highlighting this novel product at ACC.11 and the i2 Summit,” said Donald Southard, InfraRedX president and CEO. “The LipiScan IVUS permits physicians to identify both the structure – with IVUS – and chemistry – with LipiScan – of coronary plaques in a single pullback. The IVUS information is useful for determining the degree of stenosis and for guiding stenting, while the LipiScan data can identify stenotic lipid core plaques, which are at increased risk of causing peri-stenting myocardial infarction when dilated.”

In addition to the oral and poster presentations, James E. Muller, InfraRedX founder, chairman and chief medical officer gave a presentation titled “Multimodality Near-infrared Spectroscopy and IVUS Coronary Imaging: Strategies to Prevent the First Coronary Event and Improve Coronary Stenting” during the Cardiovascular Innovations Forum on April 3rd. The Forum was held in the ACC Exhibition area and a question and answer session immediately followed Dr. Muller’s presentation.

The LipiScan IVUS Coronary Imaging System employs proprietary optical imaging technology to overcome the challenges of heart motion, blood interference, and vascular access to perform NIR spectroscopic analysis of the vessel and produce a chemical map of lipid-core plaque called a Chemogram™. The system also provides physicians with a traditional IVUS image that shows plaque location, degree of stenosis and degree of stent expansion. At the same time, optical data are recorded that permit identification and colocalization of lipid core plaques. This innovative multi-modality analysis is accomplished directly in the catheterization laboratory during the coronary intervention via a single catheter pullback procedure. The data are immediately available to the physician to help guide the stenting procedure.

For more information please visit: www.infraredx.com

Premier Heart, LLC

Premier Heart, LLC exhibited the Multifunction CardioGram at ACC.11, the 60th Annual Scientific Sessions and Expo of the American College of Cardiology. Premier Heart’s MCG is being used by many physicians in the US and internationally.

The MCG offers completely non-invasive cardiac testing using “power estimate as an aid to assist physicians in diagnosis” according to its latest US FDA 510K Clearance. MCG is a chemical and radiation-free procedure, the performance of which has been shown in published clinical trials to be associated with little risk of adverse events to the patient.

According to Dr. Joseph T. Shen, founder of Premier Heart and the lead developer of Premier Heart’s Multifunction CardioGram, “Using a computational systems analysis approach we, as physicians, now have a method that analyzes and compares raw electro-cardiac data to help identify significant CAD and which has been shown in multiple studies to assist in accurate detection the presence of significant coronary artery disease requiring intervention with improved specificity and negative predictive values. MCG’s advanced technology works by sampling a
signal from two left ventricular leads (V5 and II) and performing a series of digital signal analysis operations. The operations produce a sequence of indexes, which quantify abnormalities in the mathematically transformed electro-cardiac data. This information is transferred via the Internet to Premier Heart in New York, where it is compared to a database of over 40,000 patients. A numeric score is assigned based on this analysis representing the likelihood and severity of CAD. This score is reported back to physicians within minutes to aid in detection and diagnosis in a point of care setting.

For more information please visit: www.premierheart.com

**TeraRecon**

TeraRecon, a global leader in advanced visualization and decision support solutions, showcased iNtuition CLOUD™ at the 60th Annual Scientific Session and Innovation in Intervention: i2 Summit 2011 of the American College of Cardiology (ACC.11).

TeraRecon is a global leader in advanced image processing, decision support and 3D visualization techniques. The company’s solutions provide advanced imaging support for medical and other visualization applications based on its unique and patented image processing technologies.

Jeff Sorensen, Senior Vice President, said “Cardiologists work interactively within many hospital, medical office and outpatient settings. iNtuition CLOUD provides cardiologists with uniform access to their patient’s images and delivers best-in-class advanced visualization tools everywhere. The most exciting aspect of iNtuition CLOUD is that TeraRecon can now deliver the full iNtuition experience to individual physicians with no up-front capital costs and no long-term obligation required. Our clinical tools have never been more affordable or more accessible”.

Registered iNtuition CLOUD users are granted a unique, secure account login, which can be used to upload image data and to access iNtuition. The full suite of iNtuition cardiovascular advanced visualization tools are supported including advanced coronary analysis with vessel tracking, plaque analysis, cardiac functional assessment, 4D morphological review, EP planning, calcium scoring and low-dose CT management tools. Catherization lab cine loops and ultrasound image data sets can also be viewed utilizing iNtuition CLOUD.

Robert Taylor, Ph.D., President and CEO said at the Summit, “Having achieved over 1,000 registered users in less than a year since its initial launch in 2010, iNtuition CLOUD is clearly a resounding success. The iNtuition system architecture was designed with massive scalability in mind, and iNtuition CLOUD serves as proof-positive that TeraRecon has significant technology advantages. We are also seeing increased utilization of our cloud technologies to implement ‘private cloud’ solutions which our customers own and manage themselves. TeraRecon is once again leading a rapid re-invention of advanced visualization workflow”

For more information please visit: www.terarecon.com

**Z-Medica**

Z-Medica, is home of the innovative blood clotting technology behind the QuikClot® family of products for hemostasis. Z-Medica was founded in 2002 by Francis X. Hursey, a veteran of the Apollo Project Breathing Air Team. Z-Medica exhibited the QuikClot® range at the ACC.11 Congress.

Z-Medica Corporation is proud to be the leader in the rapidly growing area of products that stop moderate to severe bleeding. First to market with the original QuikClot® brand hemostatic agent, the company continues to develop new products, technologies and delivery mechanisms that make a difference wherever bleeding presents a problem. These products make a difference around the world: from the battlefields of Iraq and Afghanistan, to the tactical law enforcement officer in Los Angeles, to the mass casualty preparedness teams in New York, to a mother in Illinois whose son’s life was saved by QuikClot® 1st ResponseTM brand. This technology has come a long way since its introduction in 2002, and along the way it has saved many lives. How do the QuikClot brand products work to stop bleeding? Z-Medica provides products based on two separate platform technologies. While the two technologies are similar and overlap in their mechanisms of action, it makes sense to discuss each separately, addressing the Kaolinite Based Products.

Kaolinite is a white alumina silicate clay material that has a long history of uses in many